These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23421411)

  • 1. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.
    Szolcsányi J; Pintér E
    Expert Opin Ther Targets; 2013 Jun; 17(6):641-57. PubMed ID: 23421411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multisteric TRPV1 nocisensor: a target for analgesics.
    Szolcsányi J; Sándor Z
    Trends Pharmacol Sci; 2012 Dec; 33(12):646-55. PubMed ID: 23068431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsaicin and sensory neurones: a historical perspective.
    Szolcsányi J
    Prog Drug Res; 2014; 68():1-37. PubMed ID: 24941663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting TRPV1 for pain relief: limits, losers and laurels.
    Szallasi A; Sheta M
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
    Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
    Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H; Pappagallo M; Szallasi A
    Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
    St Pierre M; Reeh PW; Zimmermann K
    Exp Brain Res; 2009 Jun; 196(1):31-44. PubMed ID: 19404626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
    Voight EA; Kort ME
    Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
    J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and N-oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat.
    Bölcskei K; Tékus V; Dézsi L; Szolcsányi J; Petho G
    Eur J Pain; 2010 May; 14(5):480-6. PubMed ID: 19800272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forty years in capsaicin research for sensory pharmacology and physiology.
    Szolcsányi J
    Neuropeptides; 2004 Dec; 38(6):377-84. PubMed ID: 15567473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
    Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
    J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
    Cui M; Gosu V; Basith S; Hong S; Choi S
    Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the role of lipid rafts and sphingomyelin in Ca2+-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals.
    Sághy É; Szőke É; Payrits M; Helyes Z; Börzsei R; Erostyák J; Jánosi TZ; Sétáló G; Szolcsányi J
    Pharmacol Res; 2015 Oct; 100():101-16. PubMed ID: 26238178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.